



ArQule, Inc.
Investor Relations Department
One Wall Street
Burlington, MA 01803
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ARQL

Last Trade:	1.03
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	-0.02 (-1.905%)
Day Range	1.00 - 1.08
52-Week Range	0.92 - 1.82
Volume	12,667

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need. ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy.

ArQule i... [\(more\)](#)

Stock Information



Press Releases [\[View all \]](#)

Aug 4, 2017

[ArQule Reports Second Quarter 2017 Financial Results](#)

Jul 21, 2017

[ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017](#)

Jul 11, 2017

[ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies](#)

Jun 23, 2017

[ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association \(EHA\)](#)

Jun 7, 2017

[ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 9, 2017

[Annual Report \(10-K\)](#)

Apr 13, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)